Clicky

Nkarta, Inc.(NKTX)

Description: Nkarta, Inc., a biopharmaceutical company, develops and commercializes cell therapies for cancer treatment. The company's approach for cellular immunotherapy involves chimeric antigen receptors on the surface of a natural killer (NK) cell that enable the cell to recognize specific proteins or antigens that are present on the surface of tumor cells. Its co-lead product candidates are NKX101, a pre-clinical product that enhances the power of innate NK biology to detect and kill cancerous cells; and NKX019, a pre-clinical product, which is based on the ability to treat various B cell malignancies by targeting the CD19 antigen found on these types of cancerous cells. The company was founded in 2015 and is headquartered in South San Francisco, California.


Keywords: Medicine Cancer Biopharmaceutical Biology Immune System Tumor Immunotherapy Cancer Treatment Lymphoma Gene Therapy Virotherapy Antigen Chimeric Antigen Receptor T Cell Therapies For Cancer Natural Killer Cell CD19 Chimeric Antigen Receptor Tumor Cell

Home Page: www.nkartatx.com

NKTX Technical Analysis

6000 Shoreline Court
South San Francisco, CA 94080
United States
Phone: 415 582 4923


Officers

Name Title
Mr. Paul J. Hastings CEO, Pres & Director
Dr. Nadir Mahmood Ph.D. Chief Financial & Bus. Officer
Dr. Ralph Brandenberger Ph.D. Chief Technical Officer
Dr. James Trager Ph.D., Ph.D. Chief Scientific Officer
Ms. Yvonne Li M.B.A. Chief Admin. Officer
Mr. Greg Mann VP of Public Affairs and Investor Relations
Dr. Alicia J. Hager Chief Legal Officer & Corp. Sec.
Dr. David R. Shook M.D. VP of Clinical Devel.

Exchange: NASDAQ

Country: US

Currency: US Dollar ($)

Forward PE: 0
Trailing PE: 0
Price-to-Book MRQ: 0.9096
Price-to-Sales TTM: 999999.9999
IPO Date: 2020-07-10
Fiscal Year End: December
Full Time Employees: 146
Back to stocks